Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: A meta-analysis

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 993-1001

  Saab, Sammy ^a,e   Hernandez, Jose Carlos ^b   Chi, Amanda C ^c   Tong, Myron J ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^e UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; NORFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG INDICATION; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LIVER CIRRHOSIS; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE; SYSTEMATIC REVIEW; BACTERIAL INFECTIONS; COMPLICATION; INCIDENCE; ORAL DRUG ADMINISTRATION; PERITONITIS; PROCEDURES; TIME; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIVER CIRRHOSIS; PERITONITIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 65449163888     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.3     Document Type: Article

References (26)

1. Hoefs JC, Canawati HN, Sapico FL et al. Spontaneous bacterial peritonitis. Hepatology t982;2:399-407.
2. Rimola A, Garcia-Tsao G, Nacasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. I Hepatol 2000;32:142-53.
3. Gines P, Rimola A, Planas R et al. Norfioxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12:716-24.
4. Gines P, CSrdenas A, Arroyo V et al. Management of cirrbosis and ascites. N Lngl I Med 2004;350:1646-54.
5. Fernandez J, Navasa M, Planas R et ot Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survix al in cirrhosis. Gastroenterology 2007; 133:818-24.
6. Runyon BA. AASLD practice guideline: management of adult patients witb ascites due to cirrhosis. Hepatology 2004;39:84t-56.
7. Saab 5, Ngu)en 5, Ibrahim A et al. Management of patients with cirrhosis in soutbern California: results of a practitioner survey. J Clin Gasiroenterol 2006;40:156-61.
8. Novella lvi, Sola R, Soriano G et al. Continuous vs. inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfioxacin. Hepatology t997;25:532-6.
9. Rolachon A, Cordier L, Bacq Y et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171-4.
10. Singh N, Gayowski T, Yu VL et al. Trimetboprian-sulfamelboxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122:595-8.
11. Grange JD, Roulot D, Pelletier G et al. Noriloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. I Hepatol 1998;29:430-6.
12. Soriano G, Guarner C, Teixidó M et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477-8 1.
13. Terg R, Fassio L, Guevara M et al. Ciprolloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008;48:774 9.
14. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterolog) 1986;91:1343-6.
15. Jadad AR, Moore PA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Contemp Clin Trials 1996; 17:1-12.
16. Blaise M, Pateron D, Trinchet IC et al. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994;20:34-8.
17. Hsieh WJ, Lin HC, Hwang SJ et al. The effect of ciprofioxacin in tbe prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am I Gastroenterol t998;93:962-6.
18. Soriano G, Guarner C, Tomás A et al. Norfioxacin prevents bacterial infection in cirrbotics witb gastrointestinal hemorrbage. Gastroenterology 1992; 103:1267-72.
19. Pauwels A, Mostefa-Kara N, Debenes B et al. Systemic antibiotic prophylaxis after gastrointestinal bemorrbage in cirrhotic patients witb a bigb risk of infection. Hepatology 1996;24:802-6.
20. Rimola A, Bory F, Teres I et al. Dral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985;5:463-7.
21. Caly W Strause L. A prospective study of bacterial infections in patients with cirrhosis. I Hepatol t993;18:353-8.
22. Borzio lvi, Salerno F, Piantoni L et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 200 t;33:9- 12.
23. Bernard B, Grange GI, Khac L et al. Antibiotics prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a metaanalysis. Hepatology 1 999;29:1 655-61.
24. The Redbook. Pharmacy's Fundamental Reference 2006 edition, revised edition Thomson PDR: USA, 2006.
25. Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis al. a liver transplant unit. Cliii Microbiol Infect 2003;9:531-7.
26. Wade II. Rolando N, Hayllar K et al. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995;21:1328-36.